Compile Data Set for Download or QSAR
Report error Found 12 Enz. Inhib. hit(s) with all data for entry = 13070
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM756387(US12351585, Compound 1r)
Affinity DataIC50: 0.160nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536301((E)-2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfony...)
Affinity DataIC50: 0.25nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536314((E)-2-(2-ethoxy-5-((4-(3-hydroxypropyl)piperazin-1...)
Affinity DataIC50: 0.420nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536310((E)-2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperidin-1-...)
Affinity DataIC50: 0.480nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM756386(US12351585, Compound 1o)
Affinity DataIC50: 0.530nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536306(3-(2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl...)
Affinity DataIC50: 1.5nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536316(2-(2-ethoxy-5-((4-(3-hydroxypropyl)piperazin-1-yl)...)
Affinity DataIC50: 2.80nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM756389(US12351585, Compound 1v)
Affinity DataIC50: 4.10nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM50238854(CHEBI:58987 | Revatio | Sildenafil Citrate | UK-92...)
Affinity DataIC50: 5.40nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536302(2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)ph...)
Affinity DataIC50: 12nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536315((E)-3-(4-((4-ethoxy-3-(6-((hydroxyimino)methyl)-5-...)
Affinity DataIC50: 12nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM536313((E)-2-(1-((4-ethoxy-3-(6-((hydroxyimino)methyl)-5-...)
Affinity DataIC50: 66nMAssay Description:Purpose: Evaluation of the effects of compounds of the present invention on the activity of the human phosphodiesterase-5 quantified by measuring the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent